ReutersReuters

Patritumab Deruxtecan Biologics License Application For Patients With Previously Treated Locally Advanced Or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Refinitiv阅读少于1分钟
  • PATRITUMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

登录或创建永久免费帐户以阅读此新闻